Drug Profile
Buprenorphine transdermal - Luye Pharma
Alternative Names: LY-021701Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Acino
- Developer Luye Pharma Group
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 03 Oct 2023 Buprenorphine transdermal is still in phase III trials for pain in China (Luye Pharma pipeline, October 2023)
- 06 Sep 2018 Clinical trials in Pain in China (Transdermal) before September 2018
- 06 Sep 2018 Luye Pharma Group announces intention to submit NDA to China Food and Drug Administration for Pain